

Local Clinical Excellence Award

Financial Tool Guide

For the 2023/24 award round

1. Introduction

1.1 The financial tool is a resource that will assist employers to calculate the minimum level of funds for investment in the 2023/24 LCEA award year.

1.2 The spreadsheet calculates the required investment fund minus any pre-2018 awards still in payment, any awards from 2018/19 – 2022/23 still in payment, and any reversion costs (associated with the loss of national awards). The remaining funds represent the amount of money to be spent on new awards. The spreadsheet also presents the LCEA total spend for the year.

1.3 This financial information should be included in annual reports to the trust board and JLNC. Details on the structure and publication of the report can be found in our LCEA future award round guide.

2. How to use this financial tool.

2.1 Blue cells require an input or a value of zero, all other cells are locked.

2.2 Access the financial tool [here](#)

3. Determine the investment pot for the 23/24 award round

3.1 Cell E5/6 requires the figure of the number of eligible consultants as at 1 April 2023. For these purposes 'eligible' will be defined as substantively employed consultants with at least one year's service (on 1 April of the award year) at consultant level who do not hold an NCEA, NCIA, or a distinction award. [Eligibility criteria](#).

3.2 Cell E16 requires the figure of any unspent funds from previous award rounds that are to be carried over. The contractually set minimum funds for investment should be paid annually, but there may be instances where some funds have not been spent and therefore need to be paid in 2023/24.

Local Clinical Excellence Award (LCEA) Financial Monitoring Status: 2023 - 2024 Award Round	
Determine the investment pot for the 23/24 award round	
Determine the number of eligible consultants (full-time equivalent) Cell E5/6	0
Multiply the number of eligible consultants (full-time equivalent) by £7,900.00 Minimum amount per eligible FTE	£7,900
Number of eligible consultants (full-time equivalent) as at 1 April 2023 multiplied by £7,900	£0
Add any unspent funds that need to be carried over from previous award years.	
Funds to be carried over	£0 Cell E16
Total investment fund for the 2023/24 award year	£0

Scalar	
ENIC	13.80%
EPC	20.68%
APA	10.00%

Key	
Requires input	
ENIC Only	
ENIC & EPC	
APA Only	

Image 1 – Cells E5/6 and E16

4. Take account of any pre-2018 awards in payment

4.1 Cells E25-33 and F25-33 should be populated with pre-2018 awards levels 1-9 that are still in payment prior to any reviews that take place in 2023/24. Pre-2018 LCEA will be retained for pre-2018 LCEA award holders and these awards shall remain pensionable and consolidated but subject to a review process. Pre-2018 LCEA holders will continue to receive uplifts when undertaking Additional Programmed Activities (APAs). The blue boxes require a total number of FTE and APAs that receive each level of award.

4.2 Cells G36 and H36 represent the total amount of money released as an outcome of any pre-2018 reviews that have taken place. The first review will take place five years after the date of the award of a consultant's last pre-2018 LCEA point. Scores of 11 – 15 will lose one LCEA point (and its associated cash value) and be reviewed again after three years and ≤ 10 lose two LCEA points (and their associated cash value) and be reviewed again after two years.

4.3 Cells E43-44 and F43-44 take account of National Clinical Impact Award outcomes. Any individual who has been awarded an NCEA (i.e., bronze, silver, gold, or platinum award) and whose renewal application is unsuccessful, will revert to either a Level 7 or 8 pre-2018 LCEA or will not receive an award. Scores of > 27 revert to Level 8 LCEA, 14-26 revert to Level 7 LCEA, and < 14 full loss of award payment.

Take account of any pre-2018 awards in payment						
Prior to any 2023-24 reviews. Take account of pre-2018 awards in payment.						
Level	Award Value	FTE	Number of APAs worked	Total award value £s	Total APA value £s	Total (including APAs) £s
Level 1	£3,016	0.0	0.0	£0	£0	£0
Level 2	£6,032	0.0	0.0	£0	£0	£0
Level 3	£9,048	0.0	0.0	£0	£0	£0
Level 4	£12,064	0.0	0.0	£0	£0	£0
Level 5	£15,080	0.0	0.0	£0	£0	£0
Level 6	£18,096	0.0	0.0	£0	£0	£0
Level 7	£24,128	0.0	0.0	£0	£0	£0
Level 8	£30,160	0.0	0.0	£0	£0	£0
Level 9	£36,192	0.0	0.0	£0	£0	£0
Continued payment of existing LCEAs Total		0.0	0	£0	£0	£0
Funds released as an outcome of 2023-24 pre-2018 reviews				£0	£0	£0
Total amount of pre-2018 awards in payment for the 2023-24 award year				£0	£0	£0
Total of pre-2018 awards in payment for the 2023-24 award year (including on costs)				£0	£0	£0
Take account of National Clinical Impact Awards outcomes as at 1 April 2023						
Level	Award Value	FTE	Number of APAs worked	Total award value £s	Total APA value £s	Total (including APAs) £s
Consultants whose existing National Clinical Excellence Awards have reverted at point 7		0.0	0.0	£0	£0	£0
Consultants whose existing National Clinical Excellence Awards have reverted at point 8		0.0	0.0	£0	£0	£0
Total Value of Awards		0.0	0.0	£0	£0	£0
Total National CEA Reversion costs as at 1 April 2023	Value of Awards (with APA element as appropriate)			£0	£0	£0
Total National CEA Reversion costs as at 1 April 2023 (including on costs)				£0	£0	£0

Image 2 - Cells E25-33 and F25-33, G36 and H36, E43-44 and F43-44

5. Take account of any interim and 2022/23 awards in payment

5.1 Cells E52 and E55 identify any awards that are still in payment that were awarded during the award years 2018/19 – 2022/23. We are aware that the majority of employers applied equal distribution during those award years so are unlikely to have any awards still in payment.

Take account of any interim and 2022/23 awards in payment		
Multi-year awards from the interim 2018-2022 period as at 1 April 2023	Value of Awards	£0
	including ENIC costs	£0
Multi-year awards from award year 22/23 as at 1 April 2023	Value of Awards	£0
	including ENIC costs	£0

Cells E52 and E55

Image 3 – Cells E52 and E55

6. Funds remaining for new awards and total cost

6.1 Cell E60 represents the remaining funds to be spent on new awards for the 2023/24 award year.

6.2 Cell E61 is the total cost of new awards to the employer. New LCEAs are non-consolidated and non-pensionable and can be payable for a period of up to three years, paid annually by lump sum, and do not include an uplift for those undertaking Additional Programmed Activities (APA), therefore, only employer national insurance contributions have been applied.

6.3 Cell E63 Is the total cost of legacy awards still in payment including reversions. Pre-2018 LCEAs will be retained for pre-2018 LCEA award holders and these awards remain pensionable and consolidated but subject to a review process. Pre-2018 LCEA holders will continue to receive uplifts when undertaking APAs. Therefore, employer national insurance contributions, employer pension contributions, and additional programmed activity uplifts have been applied where necessary.

6.4 Cell E64 is the total cost of the full award year including on-costs. This figure is for trust financial accounting purposes only and should not be confused with the funds available to invest in new awards.

Funds remaining for new awards and total cost		
Funds remaining to spend on new awards for 2023/24 award year (not including ENIC which will be an additional cost for trusts)	£0	Cell E60
Total cost of new awards for 2023/24 (including ENIC)	£0	Cell E61
Total cost of all awards in payment prior to the 2023/24 award round (including on-costs)	£0	Cell E63
Total cost of ALL awards in payment (including on-costs)	£0	Cell E64

Image 4 – Cell E60, E61, E63 and E64